11 – 17 of 17
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2022
-
Mark
Tip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
(
- Contribution to journal › Article
-
Mark
Content and strength of conflict of interest policies at Scandinavian Medical Schools: a cross sectional study
(
- Contribution to journal › Article
-
Mark
Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
(
- Contribution to journal › Article
- 2021
-
Mark
Drug company payments to General Practices in England: cross-sectional and social network analysis
(
- Contribution to journal › Article
-
Mark
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: A European policy review
(
- Contribution to journal › Article
-
Mark
Pharmaceutical industry self-regulation and non-transparency : country and company level analysis of payments to healthcare professionals in seven European countries
(
- Contribution to journal › Article
-
Mark
Data Transparency and Pharmaceutical Regulation in Europe : Road to Damascus, or Room without a View?
2021) p.63-94(
- Chapter in Book/Report/Conference proceeding › Book chapter
- « previous
- 1
- 2
- next »